Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30
Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40
Veracyte, Inc. 2026 Q3 - Results - Earnings Call Presentation
UBS Maintains Buy on Veracyte, Lowers Price Target to $35
Veracyte (NASDAQ:VCYT): An Undervalued Value Stock With Quality Fundamentals
Veracyte (VCYT) Reset Decipher Growth Expectations, Is The Discount Now Too Wide?
Why Is Veracyte (VCYT) Drawing Attention For Its Decipher Prostate Test?
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript
Veracyte Crashes Almost 60% On A Seismic Shift. Analysts Decipher What Went Wrong.
Veracyte (VCYT) Q3 2026 Earnings Call Transcript
Why Is Veracyte Stock Sinking Thursday?
Veracyte Inc (VCYT) Q3 2026 Earnings Call Highlights: Revenue Climbs 15% as Afirma Shines and ...
What Veracyte (VCYT) Said on Its Q3 Earnings Call
Leerink Partners Downgrades Veracyte to Market Perform, Lowers Price Target to $35
Needham Maintains Buy on Veracyte, Lowers Price Target to $46
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.